IceCure Medical Secures US Patent for Cryogen Flow Control

Ticker: ICCM · Form: 6-K · Filed: Jun 9, 2025 · CIK: 1584371

Sentiment: bullish

Topics: patent, medical-device, intellectual-property

TL;DR

IceCure Medical just got a US patent for a new cryogen flow control system – good news for cryoablation tech!

AI Summary

On June 9, 2025, IceCure Medical Ltd. announced it received a notice of patent allowance in the U.S. for a novel cryogen flow control system. This system is designed to optimize patient outcomes in cryoablation procedures. The patent is expected to enhance the company's intellectual property portfolio in the field of medical cryotherapy.

Why It Matters

This patent allowance strengthens IceCure Medical's intellectual property and could lead to improved cryoablation treatments, potentially benefiting patients and the company's market position.

Risk Assessment

Risk Level: low — The filing is an announcement of a patent allowance, which is generally positive news with limited immediate downside risk.

Key Players & Entities

FAQ

What is the specific innovation covered by the new U.S. patent allowance for IceCure Medical?

The patent allowance is for a novel cryogen flow control system designed to optimize patient outcomes in cryoablation procedures.

When did IceCure Medical receive the notice of patent allowance?

IceCure Medical received the notice of patent allowance on June 9, 2025.

What is the purpose of the cryogen flow control system mentioned in the filing?

The system is designed to optimize patient outcomes in cryoablation procedures.

What form is this SEC filing?

This is a Form 6-K, Report of Foreign Private Issuer.

Where is IceCure Medical Ltd. based?

IceCure Medical Ltd. is based in Israel, with its principal executive office located at 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504 Israel.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 9, 2025 regarding IceCure Medical Ltd. (ICCM).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing